Replies to post #25012 on CytoSorbents Corporation (CTSO)

[fantomphan]

It was only $10 per share up to a couple of years back

[hemopure36]

If your numbers are correct, then TODAY’S valuation of a yet-to-be-approved therapeutic is nearly 9 times 2025 revenues. Today, Cytosorbents, which has enormous potential, is valued at around 9 times estimated 2020 (today’s) annual revenue. I believe our potential should have us much higher now and that has nothing to do with current quarterly revenues. Potential approval and potential revenues are what eventually drives share price for legitimate biotechs with massive potential, which I believe includes Cytosorbents. That it hasn’t happened yet is not relevant.